Philip Morris International
PM
$192.98
+1.65%
Philip Morris International Inc. (PM) is a global tobacco company that sells cigarettes and reduced-risk products, including heated tobacco (IQOS), vapes (Veev), and oral nicotine (Zyn), primarily outside the United States. Created from Altria's international operations in 2008 and bolstered by the 2023 acquisition of Swedish Match, PMI is a dominant player in both traditional combustibles and next-generation nicotine products, with IQOS and Zyn leading their respective categories. The current investor narrative centers on the company's transformation toward a smoke-free future, with accelerating adoption of reduced-risk products driving revenue growth, while regulatory risks and currency headwinds remain key debates.…
PM
Philip Morris International
$192.98
Related headlines
PM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $194.86 and implied upside of +1.0% versus the current price.
Average Target
$194.86
0 analysts
Implied Upside
+1.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$171 - $210
Analyst target range
PM is covered by 14 analysts, with a consensus recommendation of 'Buy' (mean rating 1.8 on a 1-5 scale where 1 is Strong Buy). The average target price is $194.86, implying approximately +7.7% upside from the current price of $180.88. The distribution leans bullish, with no sell ratings and a majority of buy ratings. The target range spans from $171.00 (low) to $210.00 (high). The high target of $210 assumes continued strong adoption of reduced-risk products, margin expansion, and potential multiple expansion. The low target of $171 factors in regulatory headwinds, currency drag, or slower-than-expected transition to smoke-free products. The spread of $39 (23% of the average target) indicates moderate uncertainty. Recent ratings actions show stability: UBS reiterated Neutral, Morgan Stanley and Needham maintained Overweight/Buy, and Jefferies downgraded from Buy to Hold in January 2026. Overall, the analyst community is constructive but not overly exuberant, reflecting confidence in PM's transformation story tempered by known risks.
Drowning in data?
Find the real signal!
Bulls vs Bears: PM Investment Factors
PM presents a compelling transformation story, with reduced-risk products driving revenue growth and margin expansion. The bull case is supported by a PEG ratio of 0.36x, strong free cash flow, and analyst consensus Buy. However, the bear case highlights high leverage, a premium valuation versus peers, and regulatory risks. The single most important tension is whether RRP adoption can sustain double-digit growth to justify the 22x P/E premium over the industry average. Currently, the bull case has stronger evidence given accelerating RRP revenue and expanding margins, but regulatory and currency headwinds remain key risks.
Bullish
- Strong RRP Revenue Growth: Reduced-risk products (RRPs) contributed $4.379 billion in Q1 2026, up 12.3% from $3.9 billion a year ago, now 43.2% of total revenue. This shift drives higher margins and growth, with IQOS and Zyn leading their categories.
- Expanding Profit Margins: Gross margin improved to 68.1% in Q1 2026 from 67.3% a year ago, and operating margin rose to 38.4% from 38.1%. Net margin of 24.0% reflects strong pricing power and operating leverage.
- Attractive PEG Ratio: With a PEG ratio of 0.36x, PM appears undervalued relative to its earnings growth rate. This suggests the market is not fully pricing in the growth potential from RRPs.
- Strong Free Cash Flow: TTM free cash flow is $10.666 billion, supporting a dividend yield of 3.46% and debt service. Operating cash flow of $4.709 billion in Q4 2025 demonstrates consistent cash generation.
Bearish
- High Debt and Negative Equity: Debt-to-equity is -4.89 due to negative equity from share buybacks and dividends. The current ratio of 0.96 indicates tight liquidity, though strong cash flow mitigates immediate risk.
- Regulatory and Currency Headwinds: PM operates globally, facing potential excise tax increases, flavor bans, and packaging restrictions. Currency fluctuations can impact reported earnings, as seen in past quarters.
- Premium Valuation vs Peers: Trailing P/E of 22.06x is a 47% premium to the tobacco industry average of ~15x. This premium requires continued RRP growth to justify; any slowdown could lead to multiple compression.
- Slowing Combustible Revenue: While RRP grows, combustible revenue remains stable but faces long-term volume declines. Q1 2026 combustible revenue was $5.767 billion, essentially flat, as smokers switch or quit.
PM Technical Analysis
PM is in a broad recovery trend, with the stock up 4.93% over the past year and trading at $180.88, approximately 88% of its 52-week range ($142.11–$193.05). The price sits well above the 52-week low but below the high, suggesting a constructive consolidation phase rather than a breakout or breakdown. The 1-year change of -2.21% underperforms the S&P 500's +20.92%, indicating relative weakness, but the stock has been building a base since its March 2026 lows near $157. Short-term momentum is mixed: the 1-month change is -0.51% while the 3-month change is +15.77%, showing a strong recovery from the April–May pullback. The 3-month surge contrasts with the tepid 1-year performance, hinting at a potential trend reversal or mean reversion. The stock's beta of 0.405 implies it is significantly less volatile than the market, which may appeal to risk-averse investors but also explains its lagging relative strength. Key support lies at the 52-week low of $142.11, while resistance is at the 52-week high of $193.05. A breakout above $193 would signal renewed bullish momentum, while a breakdown below $142 could indicate a bearish reversal. The low beta suggests PM is a defensive holding, with price swings typically smaller than the broader market.
Beta
0.41
0.41x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$142-$195
Price range past year
Annual Return
+7.7%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +7.5% | +0.3% |
| 3m | +22.3% | +4.7% |
| 6m | +11.2% | +7.5% |
| 1y | +7.7% | +18.4% |
| ytd | +20.4% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
Revenue is on a solid growth trajectory, with Q1 2026 revenue of $10.146 billion, up 9.09% year-over-year from $9.301 billion in Q1 2025. The multi-quarter trend shows accelerating growth: Q2 2025 revenue was $10.14 billion (+7.0% YoY), Q3 2025 was $10.845 billion (+9.4% YoY), and Q4 2025 was $10.362 billion (+6.8% YoY). Revenue segments reveal that reduced-risk products (RRPs) contributed $4.379 billion (43.2% of total) in Q1 2026, up from $3.9 billion in the prior year, driving the growth while combustible products remain stable at $5.767 billion. The shift toward RRPs is a key catalyst for the investment case, as these products carry higher margins and growth potential. Profitability is robust: net income in Q1 2026 was $2.438 billion, with a net margin of 24.0%, and gross margin expanded to 68.1% from 67.3% a year ago. Operating margin improved to 38.4% from 38.1%, reflecting operating leverage. The company is consistently profitable, with net income positive in every quarter except Q4 2024 (which had a one-time charge). Margins are stable to expanding, typical for a dominant tobacco company with pricing power. The balance sheet shows high leverage: debt-to-equity is -4.89 (negative equity due to large share buybacks and dividends), and the current ratio is 0.96, indicating tight liquidity. However, free cash flow (TTM) is strong at $10.666 billion, and the company generated $4.709 billion in operating cash flow in Q4 2025. The negative equity is common for tobacco companies with high debt and accumulated dividends, but the robust cash generation supports the dividend and debt service. ROE is negative (-113.5%) due to negative equity, but ROA of 15.5% is healthy, indicating efficient asset use.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Since net income is positive ($2.438 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 22.06x, while the forward P/E is 19.87x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests a modest growth premium. Compared to the industry (tobacco), PM trades at a premium: the industry average P/E is around 15x, so PM's 22x represents a ~47% premium. This premium is justified by PM's superior growth profile, driven by its leadership in reduced-risk products (IQOS, Zyn) and higher margins relative to traditional tobacco peers. Historically, PM's trailing P/E has ranged from about 15x to 30x over the past five years. The current 22x is near the middle of that range, suggesting the stock is fairly valued relative to its own history. It is not at extreme highs (which would indicate over-optimism) nor at lows (which would signal a value trap). The PEG ratio of 0.36x (based on forward earnings growth) indicates the stock is undervalued relative to its growth rate, supporting a bullish view.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: PM's balance sheet is highly leveraged with a debt-to-equity ratio of -4.89, reflecting negative equity from aggressive share buybacks and dividends. The current ratio of 0.96 indicates that current liabilities slightly exceed current assets, posing a liquidity risk if cash flows were to decline. However, TTM free cash flow of $10.666 billion provides a strong buffer. Net income is robust at $2.438 billion in Q1 2026, but the negative equity means ROE is -113.5%, though ROA of 15.5% shows efficient asset use. The high payout ratio of 76% leaves limited room for dividend increases without earnings growth.
Market & Competitive Risks: PM trades at a trailing P/E of 22.06x, a 47% premium to the tobacco industry average of ~15x, making it vulnerable to multiple compression if growth disappoints. Regulatory risks include potential flavor bans on IQOS and Zyn, excise tax increases, and marketing restrictions in key markets like the EU and Japan. Currency fluctuations are a persistent headwind given PM's global exposure; a strong USD can reduce reported earnings. The low beta of 0.405 means PM is defensive but may lag in risk-on environments, as evidenced by its 1-year relative underperformance of -20.94% vs the S&P 500.
Worst-Case Scenario: A combination of slower RRP adoption, regulatory crackdowns (e.g., IQOS flavor bans in the EU), and a strong USD could pressure earnings. If the stock falls to its 52-week low of $142.11, an investor would lose -21.4% from the current price of $180.88. The analyst low target of $171 implies a -5.5% downside, but a severe scenario could see the stock retest the 52-week low, representing a potential loss of about $38.77 per share.
